$INM

InMed Pharmaceuticals Inc

  • NASDAQ
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$0.7724 ▼-2.228%

Last Close

VOLUME

14,522

DAY RANGE

0.7529 - 0.8295

52 WEEK

0.6521 - 3.51

Join Discuss about INM with like-minded investors

profile
@maletone #StockTraders.NET
recently

have to scale inm

66 Replies 6 👍 14 🔥

profile
@maletone #StockTraders.NET
recently

got filled on $INM

148 Replies 7 👍 13 🔥

profile
@maletone #StockTraders.NET
recently

covered some more $INM

99 Replies 13 👍 15 🔥

SA
@saeedte #StockTraders.NET
recently

$INM ffs give in

44 Replies 13 👍 12 🔥

profile
@maletone #StockTraders.NET
recently

watching $INM got short orders out

116 Replies 6 👍 6 🔥

profile
@maletone #StockTraders.NET
recently

damn $INM didnt get enough

146 Replies 15 👍 7 🔥

profile
@dros #droscrew
recently

In the coming weeks, @inmedpharma expects to begin patient enrolment in a Phase II (755-201-EB) trial for INM-755 in up to 20 epidermolysis bullosa (EB) patients with an anticipated treatment duration of 28 days. $INM

64 Replies 10 👍 13 🔥

profile
@dros #droscrew
recently

Top Earnings Th 9/23 Aft: $AIR $AEHR $AGTC $CAMP $COST $MTN $NKE $PRGS $SCHL $TCOM . Top Earnings Fri 9/24 Pre: $CCL $GTII $INM $TEDU $UXIN

97 Replies 7 👍 9 🔥

AN
@andres168 #StockTraders.NET
recently

ok im inm again lol

105 Replies 8 👍 11 🔥

profile
@maletone #StockTraders.NET
recently

$nio coming inm

139 Replies 6 👍 11 🔥

profile
@maletone #StockTraders.NET
recently

inm $GME short currently

70 Replies 8 👍 13 🔥

Key Metrics

Market Cap

11.31 M

Beta

1.66

Avg. Volume

116.77 K

Shares Outstanding

14.64 M

Yield

0%

Public Float

0

Next Earnings Date

Next Dividend Date

Company Information

InMed Pharmaceuticals is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol ('CBN'), in diseases with high unmet medical need. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs.

CEO: Eric Adams

Website:

HQ: Suite 310, 815 W. Hastings Street Vancouver, V6C 1B4 British Columbia

Related News